Study Summary
This trial is studying the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical transplantation for the treatment of primary or secondary myelofibrosis.
Eligible Conditions
- Primary Myelofibrosis
- Secondary Myelofibrosis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: 3 years
1 year
NRM
3 years
Overall survival
At 1 year
Incidence of relapse
Day 100
Non-relapse mortality (NRM)
Up to 3 years
Incidence and severity of acute and chronic graft versus host disease (GVHD)
Incidence of severe (grade 3 or 4) cytokine release syndrome
Probability of primary and secondary graft failure
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Side Effects for
Arm II (TBI, Transplant, GVHD Prophylaxis)
23%Blood/Bone marrow
11%Cardiovascular
9%Pulmonary
7%Hepatic
7%Gastrointestinal
5%Graft versus host disease with infection and organ failure
2%respiratory failure
2%Hemorrhage
2%subdural hematoma
2%thrombosis
2%Dermatology/Skin
2%Renal/Genitourinary
2%Metabolic/Laboratory
Trial Design
1 Treatment Group
Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)
1 of 1
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: Peripheral Blood Stem Cell Transplantation · No Placebo Group · Phase 2
Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)Experimental Group · 9 Interventions: Cyclophosphamide, Recombinant Granulocyte Colony-Stimulating Factor, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, JAK Inhibitor, Melphalan, Fludarabine, Total-Body Irradiation · Intervention Types: Drug, Biological, Drug, Procedure, Drug, Drug, Drug, Drug, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
Mycophenolate mofetil
FDA approved
Peripheral Blood Stem Cell Transplantation
1997
Completed Phase 3
~1360
Tacrolimus
FDA approved
Mechlorethamine
FDA approved
Fludarabine
FDA approved
Total-Body Irradiation
1997
Completed Phase 3
~1220
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
Who is running the clinical trial?
Fred Hutchinson Cancer CenterLead Sponsor
530 Previous Clinical Trials
1,303,717 Total Patients Enrolled
12 Trials studying Primary Myelofibrosis
671 Patients Enrolled for Primary Myelofibrosis
Fred Hutchinson Cancer Research CenterLead Sponsor
443 Previous Clinical Trials
149,041 Total Patients Enrolled
11 Trials studying Primary Myelofibrosis
641 Patients Enrolled for Primary Myelofibrosis
Rachel B. SalitPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium
3 Previous Clinical Trials
190 Total Patients Enrolled
2 Trials studying Primary Myelofibrosis
144 Patients Enrolled for Primary Myelofibrosis
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are a potential hematopoietic stem cell transplant candidate.
You are able to understand the nature and significance of the study and the risks and benefits of participating in the study.
Creatinine clearance must be > 60 ml/min.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments